Bio-Path to Present Data at ASCO Annual Meeting

Bio-Path Holdings, Inc., a biotechnology firm known for its DNAbilize® liposomal delivery and antisense technology, has announced its upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to June 4, 2024, in Chicago, IL. This presentation will cover the interim results from the Phase 2 clinical trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML).

Maro Ohanian, D.O., from the Department of Leukemia at the University of Texas MD Anderson Cancer Center, will present the data. The interim results demonstrate that prexigebersen, in combination with decitabine and venetoclax, is well-tolerated and shows promising efficacy in both newly diagnosed and refractory/relapsed AML patients. The results in these cohorts have surpassed those seen with frontline therapies.

Peter Nielsen, CEO of Bio-Path, expressed his enthusiasm about the selection of their abstract by the ASCO Scientific Program Committee for an oral presentation. He emphasized that ASCO, being the world's largest clinical cancer research meeting with over 30,000 oncology professionals, provides an ideal platform to showcase these significant findings. This exposure is expected to enhance awareness of prexigebersen and may encourage greater involvement in ongoing and future studies of the drug.

The oral presentation, titled "Interim Safety and Efficacy of BP1001 in a Phase II Acute Myeloid Leukemia Study," is scheduled for Saturday, June 1, 2024, at 8:00 AM CT at McCormick Place. The presentation will be a part of a Rapid Oral Abstract Session and will carry the abstract number 6511.

Bio-Path Holdings focuses on developing DNAbilize®, a novel technology platform that enables the delivery of RNAi nanoparticle drugs through intravenous transfusion. The company's lead product candidate, prexigebersen, targets the Grb2 protein and is currently in a Phase 2 trial for blood cancers. Additionally, BP1001-A, a modified version of prexigebersen, is undergoing a Phase 1/1b study for solid tumors.

Bio-Path's second product, BP1002, targets the Bcl-2 protein and is being evaluated for treating both blood cancers and solid tumors, including lymphoma and AML. The company also plans to file an Investigational New Drug (IND) application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide, designed to inhibit STAT3 specifically.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!